Brokerages expect Miragen Therapeutics, Inc. (NASDAQ:MGEN) to post earnings of ($0.26) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Miragen Therapeutics’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.22). Miragen Therapeutics posted earnings per share of ($0.60) during the same quarter last year, which would suggest a positive year over year growth rate of 56.7%. The business is scheduled to announce its next earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Miragen Therapeutics will report full year earnings of ($1.17) per share for the current fiscal year, with EPS estimates ranging from ($1.57) to ($0.95). For the next fiscal year, analysts expect that the company will report earnings of ($1.52) per share, with EPS estimates ranging from ($2.31) to ($1.04). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Miragen Therapeutics.
Miragen Therapeutics (NASDAQ:MGEN) last issued its earnings results on Wednesday, March 14th. The medical research company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $1.22 million. Miragen Therapeutics had a negative return on equity of 63.57% and a negative net margin of 662.30%.
Several research analysts recently commented on MGEN shares. Deutsche Bank started coverage on Miragen Therapeutics in a research report on Thursday, March 22nd. They issued a “buy” rating and a $15.00 target price for the company. Zacks Investment Research lowered Miragen Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 25th. Cann started coverage on Miragen Therapeutics in a research note on Friday, January 12th. They set an “outperform” rating and a $13.00 price objective for the company. Evercore ISI started coverage on Miragen Therapeutics in a research note on Friday, March 9th. They set an “outperform” rating and a $19.00 price objective for the company. Finally, Oppenheimer started coverage on Miragen Therapeutics in a research note on Friday, January 12th. They set an “outperform” rating and a $13.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Miragen Therapeutics has an average rating of “Buy” and an average price target of $16.31.
In other Miragen Therapeutics news, Director Bruce Booth bought 545,454 shares of the stock in a transaction dated Tuesday, February 13th. The stock was bought at an average cost of $5.50 per share, for a total transaction of $2,999,997.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Adam Scott Levy bought 9,090 shares of the stock in a transaction dated Tuesday, February 13th. The stock was acquired at an average price of $5.50 per share, with a total value of $49,995.00. Following the completion of the purchase, the insider now owns 10,540 shares of the company’s stock, valued at approximately $57,970. The disclosure for this purchase can be found here. Corporate insiders own 44.40% of the company’s stock.
Large investors have recently made changes to their positions in the company. Virtu Financial LLC increased its stake in shares of Miragen Therapeutics by 372.8% in the fourth quarter. Virtu Financial LLC now owns 51,896 shares of the medical research company’s stock valued at $541,000 after buying an additional 40,920 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Miragen Therapeutics in the third quarter valued at $250,000. Aveo Capital Partners LLC acquired a new stake in shares of Miragen Therapeutics in the fourth quarter valued at $279,000. Russell Investments Group Ltd. acquired a new stake in shares of Miragen Therapeutics in the third quarter valued at $147,000. Finally, Deutsche Bank AG increased its stake in shares of Miragen Therapeutics by 437.4% in the fourth quarter. Deutsche Bank AG now owns 60,917 shares of the medical research company’s stock valued at $634,000 after buying an additional 49,581 shares in the last quarter. Institutional investors own 18.98% of the company’s stock.
Shares of MGEN stock opened at $6.50 on Wednesday. The firm has a market capitalization of $205.17, a P/E ratio of -4.71 and a beta of 1.33. Miragen Therapeutics has a one year low of $5.01 and a one year high of $15.91. The company has a debt-to-equity ratio of 0.26, a current ratio of 13.33 and a quick ratio of 13.33.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect Miragen Therapeutics, Inc. (MGEN) to Announce -$0.26 Earnings Per Share” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/zacks-analysts-expect-miragen-therapeutics-inc-mgen-to-announce-0-26-earnings-per-share.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.